Tianjin Medical University

Greater efforts urged to give AI full play

Retrieved on: 
Thursday, May 18, 2023
Intelligence, Air Force Life Cycle Management Center, Vision China Times, Human, University, Communist party, Face, Internet, Committee, Social science, Hoxhaism, Publicity Department of the Chinese Communist Party, Privacy, Science, Congress, Developed country, Tianjin Medical University, Artificial intelligence, Diagnosis, Safety, Medical device, Sales, Microsoft, China Daily, AI

The event is part of the ongoing 7th World Intelligence Congress, which started on Thursday and runs through Sunday in Tianjin.

Key Points: 
  • The event is part of the ongoing 7th World Intelligence Congress, which started on Thursday and runs through Sunday in Tianjin.
  • Wei Qing, Microsoft (China) Ltd's chief technology officer, said no matter how powerful AI is, it is a machine's capability.
  • AI is gradually being implemented in the medical field, covering screening, diagnosis, treatment and predictions, said Yan Hua, Party secretary of Tianjin Medical University.
  • Although AI brings new development opportunities, there are still challenges to face, she added.

Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD

Retrieved on: 
Thursday, February 2, 2023
Dai, Quinze-Vingts National Ophthalmology Hospital, Tianjin Medical University, Patient, Clinical trial, Therapy, Severe cognitive impairment, AAV, Pharmaceutical industry

and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, at the Ophthalmology Hospital of Tianjin Medical University in Tianjin, China.

Key Points: 
  • and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, at the Ophthalmology Hospital of Tianjin Medical University in Tianjin, China.
  • FT-003 is being studied for the treatment of neovascular or wet age-related macular degeneration (wAMD) and is Frontera’s second gene therapy product candidate to enter the clinic.
  • “I am excited by the momentum the Frontera team has achieved so far this year with the dosing of the first patients in two gene therapy Phase 1 clinical trials during the month of January for FT-001 and FT-003,” said Yong Dai, Ph.D., founder and CEO of Frontera.
  • “FT-003 is designed as a one-time treatment for patients with wet-AMD, a leading cause of blindness globally in people over 60 years old.

YDS Pharmatech helps uncover a novel viral recognition pathway: published in Nature Chemical Biology

Retrieved on: 
Thursday, August 18, 2022
YDS, Drug discovery, CEO, Molecule, AI, Nature Chemical Biology, Research, Membrane protein, Degenerative disease, Therapy, PROTAC, COVID-19, Tianjin Medical University, Norovirus, Plasma protein binding, Drug design, Ubiquitin, Virus, Enterovirus, Biology, MBA, Severe acute respiratory syndrome coronavirus 2, MD, LinkedIn, Vaccine

ALBANY, N.Y., Aug. 18, 2022 /PRNewswire/ -- YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today.

Key Points: 
  • ALBANY, N.Y., Aug. 18, 2022 /PRNewswire/ -- YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today.
  • The company helped reveal a new viral protein recognition mechanism, highlighting a promising new target for antiviral drugs.
  • Recently, TRIM7 was also shown to have activity against human enterovirus, but the mechanism by which TRIM7 recognizes viral proteins remained unknown.
  • In this study, YDS Pharmatech helped identify the specific molecular mechanism by which TRIM7 recognizes viral infection.

Ping An's AI-driven AskBob Doctor Earns Top Scores in Diabetes Management Competition

Retrieved on: 
Tuesday, December 7, 2021
People, International Diabetes Federation, Universe People, Database, University of São Paulo, Peking University International Hospital, Tianjin Medical University, Insurance, Ribeirão, Technology, Hospital, Singapore, Metabolism, Central Hospital, Shanghai Sixth People's Hospital, Moyamoya disease, Ping'an, IDF, Hyperlipidemia, Hypertension, Patient, Efficiency, Lists of diseases, Singapore General Hospital, Head, Diabetes, Roger Hawkins (drummer), Diabetic nephropathy, Peking University, Department, Senior Consultant, University, Diabetic retinopathy, International, Huế Central Hospital, Diagnosis, Speech, AI, São Paulo, Artificial intelligence, American Association of Clinical Endocrinologists, Medical device, Health insurance, Pharmaceutical industry

The competition was jointly organized by the International Diabetes Federation (IDF), Ping An Smart City, Ping An Technology, Ping An Good Doctor, Peking University People's Hospital and Peking University International Hospital.

Key Points: 
  • The competition was jointly organized by the International Diabetes Federation (IDF), Ping An Smart City, Ping An Technology, Ping An Good Doctor, Peking University People's Hospital and Peking University International Hospital.
  • AskBob Doctor was manually operated by a Ping An representative.
  • After a thorough evaluation by the judges, AskBob Doctor scored 92.4 points on average while the endocrinologists' team scored 89.5 points.
  • In addition, AskBob Doctor's response speed was impressive: AskBob Doctor took just a few seconds to complete one case, while a human doctor took nearly 20 minutes.